'Unconvincing' two-year data for newly approved Eylea
This article was originally published in Scrip
Executive Summary
Two-year data reported by Regeneron Pharmaceuticals and Bayer HealthCare on the wet age-related macular degeneration (AMD) drug, Eylea (aflibercept), have been ill-received by some analysts.